• br Implementation of sacubitril valsartan into clinical prac

  2024-11-04

  

  Implementation of sacubitril/valsartan into clinical practice Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial; NYHA functional class II–IV, reduced left ventricular ejectio

• Initially DPP DPP and prolyl tripeptidyl peptidase A

  2024-11-04

  

  Initially, DPP4, DPP7, and prolyl tripeptidyl peptidase A (PtpA) were the only exopeptidases identified in P. gingivalis. These share substrates according to their altered specificities, as DPP4 is highly specific for Pro at the penultimate position from the N-terminus (P1 position), though it accep

• br Experimental Procedures br Acknowledgments

  2024-11-04

  

  Experimental Procedures Acknowledgments We thank the members of the Qing laboratory for helpful suggestions and Biotree Biotech Co., Ltd. (Shanghai, China) for metabolomics analysis and data interpretation. This study was supported by the National Key Research and Development Program of China

• br Disclosure br Acknowledgments br Introduction Deeper unde

  2024-11-04

  

  Disclosure Acknowledgments Introduction Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small Berberine that target genetic mutations known to play critical roles in the progression to metastatic disease. Mutations in epidermal g

• br Disclosure br Acknowledgments br Introduction Deeper unde

  2024-11-04

  

  Disclosure Acknowledgments Introduction Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small cyclic adenosine monophosphate that target genetic mutations known to play critical roles in the progression to metastatic disease. Mut

• br AHR mediates TCDD toxicity and wasting

  2024-11-04

  

  AHR mediates TCDD toxicity and wasting syndrome TCDD causes numerous toxicities in laboratory animals, including teratogenesis, hepatic steatosis, thymic atrophy, immune dysfunction and a lethal wasting syndrome [17]. The dose-dependent sensitivity to TCDD-induced toxicities varies widely among l

• br New AMPK activators Fenofibrate is a

  2024-11-04

  

  New AMPK activators Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal fu

• AZD 7762 Ethanol can affect biological systems directly or a

  2024-11-04

  

  Ethanol can affect biological systems directly, or also through the interactions between these systems, which become important in the actions promoted by alcohol consumption. Its metabolites acetaldehyde and acetate play a key role in the AZD 7762 mediating some effects of ethanol (Israel et al., 1

• br Conclusion Biotransformation of trachyloban oic acid by S

  2024-11-04

  

  Conclusion Biotransformation of trachyloban-19-oic amc 7 synthesis by S. racemosum provided three products. Oxidation of compound 1 at C-17 (2–3), as well as rearrangement of 1 into a kaurane diterpene hydroxylated in C-16 and C-17 (4) were crucial for increasing AChE inhibitory activity. Compoun

• br Materials and methods br Results The

  2024-11-04

  

  Materials and methods Results The determination of the intrinsic inhibitory potential of the oximes HI-6 and MMB-4 with human and guinea pig AChE revealed marked differences between both oximes (Table 1). MMB-4 had an only marginal effect on both AChE species, calculated IC50 of >1000μM, while

• The difficulty of characterizing nAChRs in the central nervo

  2024-11-04

  

  The difficulty of characterizing nAChRs in the central nervous system is also exemplified by early observations that nicotine caused no detectable effect when applied on a brain slice and it is only with the focal and high time resolution of more recent experiments that the effects of nicotinic neur

• bv8 Imatinib is a well known anticancer drug used in Chronic

  2024-11-01

  

  Imatinib is a well-known anticancer drug used in Chronic Myeloid Leukemia (CML) against the altered expression/activity of tyrosine kinase resulting from the fusion of BCR-ABL in leukemic blasts. It has been demonstrated that Imatinib can induce autophagy in BCR-ABL expressing bv8 (K562 cell line a

• br Materials and methods br Results and

  2024-11-01

  

  Materials and methods Results and discussion In our previous studies (Matarneh et al., 2017), mitochondria were mechanically disrupted and separated into supernatant and pellet fractions by centrifugation. The causative agent for enhnced glycolytic flux was shown to be a protein that resides i

• br Conflicts of interest br Newly

  2024-10-31

  

  Conflicts of interest Newly Identified Mechanisms of APN Resistance Hold Therapeutic Potential APN, APN Receptors, and APN Cardiovascular Protection APN Resistance in Cardiovascular Disease The Molecular Mechanisms of APN Resistance Concluding Remarks and Future Directions Finally,

• br Materials and methods br Results

  2024-10-31

  

  Materials and methods Results and discussion Conclusion Amino-functionalized mesoporous TiO2-NH2 microparticles were used to immobilize ADA, followed by GLU cross-linking. The mesopores provided a natural microenvironment with sufficient room for the enzyme to efficiently perform its cataly

15466 records 57/1032 page Previous Next First page 上5页 5657585960 下5页 Last page